Shionogi & Co., Ltd. (TYO:4507)

Japan flag Japan · Delayed Price · Currency is JPY
2,382.00
-6.50 (-0.27%)
May 28, 2025, 3:30 PM JST
3.25%
Market Cap 2.03T
Revenue (ttm) 438.30B
Net Income (ttm) 170.40B
Shares Out 850.69M
EPS (ttm) 200.31
PE Ratio 11.89
Forward PE 11.76
Dividend 58.00 (2.43%)
Ex-Dividend Date Mar 28, 2025
Volume 1,957,800
Average Volume 2,681,770
Open 2,400.50
Previous Close 2,388.50
Day's Range 2,382.00 - 2,424.00
52-Week Range 1,944.66 - 2,469.50
Beta 0.12
RSI 56.76
Earnings Date May 12, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956... [Read more]

Sector Healthcare
Founded 1878
Employees 4,955
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4507
Full Company Profile

Financial Performance

In 2024, Shionogi &'s revenue was 438.30 billion, an increase of 0.74% compared to the previous year's 435.08 billion. Earnings were 170.40 billion, an increase of 5.17%.

Financial Statements

News

Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder

Large-Scale Research and Grassroots Patient Advocacy Collaborations Led to Historic Milestone for Rare Disease Community Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshir...

4 months ago - Benzinga

Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ETCompany ParticipantsYoshimasa Kyokawa - VP, Corporate...

4 months ago - Seeking Alpha

Shionogi & Co. reports 9M results

4 months ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chair...

7 months ago - Seeking Alpha

Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content]

Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.

9 months ago - EURACTIV.com

Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice Presi...

10 months ago - Seeking Alpha

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...

1 year ago - Business Wire

Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Di...

1 year ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Office...

1 year ago - Seeking Alpha

Shionogi: Likely The Last Viable COVID Play

Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.

2 years ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and A...

2 years ago - Seeking Alpha